Evidence map›Paper›PMID 34284753›Full record

ArticleBMC cancer2021

Ferroptosis-related gene signature predicts the prognosis in Oral squamous cell carcinoma patients.

Hongyu Li, Xiliu Zhang, Chen Yi, Yi He, Xun Chen, Wei Zhao, Dongsheng Yu

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. NCOA7 promotes OSCC progression by inhibiting ROS-regulated ferroptosis.Cellular and molecular life sciences : CMLS · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hongyu Li *Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, 510030, Guangdong, China.
Xiliu Zhang *Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, 510030, Guangdong, China.
Chen Yi *Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, 510030, Guangdong, China.
Yi HeHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, 510030, Guangdong, China.
Xun ChenHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, 510030, Guangdong, China.
Wei ZhaoHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, 510030, Guangdong, China. zhaowei3@mail.sysu.edu.cn.
Dongsheng YuHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, 510030, Guangdong, China. yudsh@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-2176-9308
Sun Yat-sen University · CNStomatology Hospital · CN

Funding

National Natural Science Foundation of China 81873711National Natural Science Foundation of China 82073378
6 · The paper itself

Abstract

backgroundThe prognosis of oral squamous cell carcinoma (OSCC) patients is difficult to predict or describe due to its high-level heterogeneity and complex aetiologic factors. Ferroptosis is a novel form of iron-dependent cell death that is closely related to tumour growth and progression. This study aims to clarify the predictive value of ferroptosis-related genes (FRGs) on the overall survival(OS) of OSCC patients.

methodsThe mRNA expression profile of FRGs and clinical information of patients with OSCC were collected from the TCGA database. Candidate differentially expressed ferroptosis-related genes (DE-FRGs) were identified by analysing differences between OSCC and adjacent normal tissues. A gene signature of prognosis-related DE-FRGs was established by univariate Cox analysis and LASSO analysis in the training set. Patients were then divided into high- and low-risk groups according to the cut-off value of risk scores, A nomogram was constructed to quantify the contributions of gene signature and clinical parameters to OS. Then several bioinformatics analyses were used to verify the reliability and accuracy of the model in the validation set. Finally, single-sample gene set enrichment analysis (ssGSEA) was also performed to reveal the underlying differences in immune status between different risk groups.

resultsA prognostic model was constructed based on 10 ferroptosis-related genes. Patients in high-risk group had a significantly worse OS (p < 0.001). The gene signature was verified as an independent predictor for the OS of OSCC patients (HR > 1, p < 0.001). The receiver operating characteristic curve displayed the favour predictive performance of the risk model. The prediction nomogram successfully quantified each indicator's contribution to survival and the concordance index and calibration plots showed its superior predictive capacity. Finally, ssGSEA preliminarily indicated that the poor prognosis in the high-risk group might result from the dysregulation of immune status.

conclusionThis study established a 10-ferroptosis-releated gene signature and nomogram that can be used to predict the prognosis of OSCC patients, which provides new insight for future anticancer therapies based on potential FRG targets.

Indexed as

Biomarkers, TumorCarcinoma, Squamous CellFerroptosisGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedMouth NeoplasmsPrognosisBiomarkers, TumorFerroptosisGene prognosis signatureImmunityNomogramOral squamous cell carcinoma

Identifiers

PMID34284753
PMCPMC8290602
OpenAlexW3183777361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.